Genetron Holdings Limited - GTH STOCK NEWS

Genetron Health, a leading precision oncology platform company in China, announced shareholder approval for a merger, making it a wholly owned subsidiary of Parent. Approximately 75.4% of total ordinary shares voted in favor, with 99.9% approval for the Merger Agreement. The completion of the Merger is subject to specific conditions, leading to the Company becoming privately held and delisting from Nasdaq.

Genetron Health, a leading precision oncology platform company in China, has called an extraordinary general meeting of shareholders to consider and vote on the proposal to authorize and approve the previously announced agreement and plan of merger. If consummated, the Merger would result in the Company becoming a privately held company and its American depositary shares would no longer be listed or traded on any stock exchange. Shareholders and ADS holders as of specific dates are entitled to attend and vote at the EGM.

Genetron Health announces merger agreement with New Genetron Holding Limited

The Smart in Vitro Diagnostics report provides comprehensive insights into the AI IVD market, highlighting its growth driven by advancements in technology and demand for new testing regimes. Key developments include AI applications in diagnostics, with companies like Viome Life Sciences raising $67M for AI cancer diagnostics. The report outlines market trends such as decentralization and the role of bioinformatics, and forecasts demand in 18 countries. It also lists factors both driving and limiting growth in the sector, positioning stakeholders for strategic investments in this evolving market.

The global in vitro diagnostics market is anticipated to grow from $105.23 billion in 2022 to $127.56 billion by 2028, reflecting a CAGR of 3.26%. Key trends include the shift from conventional instruments to advanced, automated analyzers and the integration of AI and cloud technology, fostering rapid and cost-effective testing solutions. Advances in molecular diagnostics and an increase in product launches, including M&A activities, are transforming healthcare outcomes. The reagents and consumables segment holds the largest market share, while the immune & clinical chemistry segment dominates by technology. A significant demand for diagnostics related to chronic and infectious diseases propels market growth.

The global genomic cancer panel and profiling market is experiencing rapid growth as physicians increasingly utilize comprehensive data in cancer diagnosis and treatment. A recent report indicates a shift from a niche market to mainstream adoption among oncologists, highlighting the potential for premium pricing on effective diagnostics. The report provides detailed insights across 18 countries and forecasts demand for advanced testing regimes. Key players are expanding globally, with advancements in sequencing technology and significant trends impacting market dynamics. Assistance for growth estimates is provided, facilitating decision-making in clinical facilities.

The Molecular Diagnostics for Cancer report, released on February 9, 2023, provides comprehensive data to analysts and planners, including the latest Medicare Fee Payment Schedules for test pricing. It emphasizes growth in pharmacogenomics, personalized medicine, and liquid biopsy, projecting a dynamic global market despite potential disruptions from the COVID-19 pandemic. The report details market insights across 18 countries and includes profiles of over 120 companies. Key trends such as the emergence of new economies and the role of genetic material in health are highlighted, showing a promising outlook for the diagnostics industry.

The newly released report by ResearchAndMarkets.com highlights the significant growth potential of the global Liquid Biopsy market from 2023 to 2027. The market has transitioned from development to growth, influenced by advancements in cancer diagnostics. The report analyzes market size forecasts by cancer type, usage, and geographic location. Key findings include the impact of COVID-19, technological innovations like Circulating Tumor Cells and Cell-Free DNA, and a detailed examination of market trends and players. Investors are encouraged to make informed decisions based on the latest data and projections concerning this evolving sector.